Livdelzi (seladelpar)
$13,170.00
We can help with your prescription. Read the “Prescription Guide”.
You can access this medicine even if it’s not approved in your country. Learn how.
Livdelzi (seladelpar) is a prescription medicine for the treatment of adults with primary biliary cholangitis (PBC). It can be used in combination with ursodeoxycholic acid (UDCA) for patients who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA 1.
Livdelzi (seladelpar) is currently only approved in the USA 2.
Buy Livdelzi (seladelpar)
What is Livdelzi (seladelpar) for?
Livdelzi (seladelpar) is indicated for the treatment of primary biliary cholangitis (PBC) in adult patients. It can be used in combination with ursodeoxycholic acid (UDCA) for patients who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA [1].
Livdelzi (seladelpar) is available as capsules (10 mg) [1].
How does Livdelzi (seladelpar) work?
Livdelzi (seladelpar) activates a protein called PPAR-delta (δ), which may help reduce bile acid production, though the exact way it benefits patients with primary biliary cholangitis (PBC) is unclear. Research suggests that seladelpar lowers bile acid levels by decreasing the activity of an enzyme called CYP7A1 through a process involving the protein FGF21 [1].
Where has Livdelzi (seladelpar) been approved?
Livdelzi (seladelpar) is currently only approved by the FDA in the USA [2].
References:
- Highlights of prescribing information. Accessdata.fda.org, Accessed 20 August 2024.
- Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA. Gilead, Accessed 20 August 2024.
| Livdelzi 10 mg oral capsule | 13,170 |
|---|
Be the first to review “Livdelzi (seladelpar)”
Related products
Alagille Syndrome
Primary biliary cholangitis (PBC)
Reviews
There are no reviews yet.